课题基金 / 基金详情

HLA AND TRANSPLANTATION

HLA AND TRANSPLANTATION
HLA 和移植
批准号:
3224355
负责人:
PAUL I TERASAKI
金额:
$12.18万
依托单位国家:
美国
项目类别:
财政年份:
1976
资助国家:
美国
项目状态:
已结题
起止时间:
1976-12-01 至 1992-06-30

项目摘要

项目成果

PAUL I TERASAKI的其他基金

相似基金

相关文献

中文摘要
翻译
该项目的主要目的将是继续研究同种异体移植物。 有问题。对影响移植存活的因素的研究将被利用 过去12年收集的大量数据库和分析将 使用现场计算机设施完成。需要检查的因素包括 HLA-DR组织相容性匹配,可能的增强型抗体,以及 输液效果。将努力制定出一种方法,通过这种方法 可以检测到输血诱导的增强抗体。来自中国的血清 随后拒绝移植的患者将与那些 成功的移植手术。抗免疫球蛋白抗体是主要的 被认为是增强抗体的抗体。
英文摘要
The primary aim of this project will be continued study of the allograft problem. Studies of factors influencing transplant survival will utilize an extensive data base collected over the past 12 years and analyses will be done using an on-site computer facility. Factors to be examined include HLA-DR histocompatibility matching, possible enhancing antibodies, and the transfusion effect. Efforts will be made to devise means by which enhancing antibodies induced by transfusiuons can be detected. Sera from patients who subsequently reject grafts will be compared to those with successful grafts. Antimmunoglobulin antibodies are the principal antibodies postulated to be enhancing antibodies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PROSTATE, LUNG, COLORECTAL, AND OVARIAN (PLCO) CANCER
PROSTATE, LUNG, COLORECTAL, AND OVARIAN (PLCO) CANCER
MONOCLONAL ANTIBODIES TO TREAT KIDNEY GRAFT REJECTION
MONOCLONAL ANTIBODIES TO TREAT KIDNEY GRAFT REJECTION
海外基金